SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe Senesac who wrote (2476)1/22/1999 2:38:00 PM
From: Steven C. Vartan  Read Replies (1) of 2553
 
Also noticed up 13% on almost 10 times average volume. I recently read a Wedbush Morgan report on a number of Biotech in Woundcare. While the focus was on Epicel type products they had the following comments onf GENZL: Epicel sales flat for 8Quarters then jumped up to 1.7 million in Q3 of 1998; each patient needs $79,000 of epicel; unlike some other companies GENZL has diverse portfolio (not a one trick pony); If misery likes company they had a graph showing biotech in general up 45% for the year while companies like GENZL were off an average of 55% for the year. All the big brokers are still primarily bullish only on the large profitable companies. IMO once GENZL can give guidance that it will be profitable we will move up sharply.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News